ArchiveGlucocorticoid (GC) has been widely used to treat inflammatory diseases, with significant therapeutic effects, but accompanied by a series of adverse reactions, including immunosuppression, osteoporosis, hyperglycemia, hypertension, cognitive problems, and digestive system diseases. By regularly monitoring the patients' physiological indicators and symptoms, the dosage of GC can be dynamically adjusted. Rational dietary management, bone density monitoring, and blood pressure monitoring are also key components to prevent adverse reactions. Alternative therapy can reduce patients' dependence on GC. Gene analysis and personalized therapy are expected to further optimize the efficacy of GC. This article reviewed the common adverse reactions of GC in clinical practice, explored prevention strategies through in-depth understanding of its mechanisms, to maximize the safety and efficacy of medication.
Glucocorticoid (GC) is a type of steroid hormone, excessive or insufficient GC can affect pregnancy status and fetal development. Therefore, it is crucial to avoid unnecessary hormone exposure in the fetus while achieving the best therapeutic effect. This article reviewed the application and related adverse reactions of GC in pregnancy in recent years, aiming to provide reference for clinical practice.
Corona virus disease 2019 (COVID-19) often presents with respiratory symptoms, and also leads to multiple organ failure, which can be life-threatening. Severe inflammation leads to cytokine storms, which are associated with organ dysfunction, disease severity, and mortality. Therefore, controlling high inflammatory response is crucial for the treatment of COVID-19. Glucocorticoid (GC) is one of the important drugs for controlling high inflammatory response. This article reviewed the safety and effectiveness of GC in the treatment of COVID-19 in recent years, aiming to provide reference for clinical practice.
Glucocorticoid (GC) is widely used in the treatment of inflammation and immune system diseases, but long-term and high-dose use can cause various drug-related adverse reactions, including GC induced osteoporosis (GIO). Excessive GC can have harmful effects on bone cells, leading to impaired bone formation and resorption. Therefore, all long-term users of GC need to undergo regular fracture risk assessments. The article discussed the pathogenesis, clinical manifestations, fracture risk, and treatment strategies of GIO, to provide some reference for clinical practice.
To observe the efficacy and anti-inflammatory activity of Ruangan Zhuyu formula in the treatment of high-fat diet-induced nonalcoholic steatohepatitis (NASH) in mice, and to provide data support for its clinical application.
Forty-two C57BL/6 mice were randomly divided into model group, normal group, Silibinin Capsules group, Ruangan Zhuyu formula low, medium, and high dosage groups, seven mice in each group. The NASH model was induced in mice by feeding with high-fat diet for 14 weeks. After successful modelling, Ruangan Zhuyu formula each dose groups and the Silibinin Capsules group were given 1 ml drug solution every day by intragastric administration for 13 weeks on the basis of high-fat diet. The changes of body mass in each group were recorded. The mice were executed 2 weeks after the administration was stopped, and blood samples were collected to detect the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), laminin (LN), hyaluronic acid (HA), interleukin (IL)-2, IL-4, IL-6, IL-10 and interferon α(IFN-α). Hematoxylin-eosin (HE), oil-red, and Masson staining were used to observe the hepatic steatosis, fat droplet accumulation, and hepatic fibrosis.
Compared with the model group, the body mass of mice in Ruangan Zhuyu formula group decreased significantly (P<0.05). The serum AST level in Ruangan Zhuyu formula high-dose group decreased significantly (P<0.05), the serum ALT level in Ruangan Zhuyu formula medium and high-dose groups decreased significantly (P<0.05), the level of IL-4, IL-6, IL-10 and IFN-α decreased significantly (P<0.05). The level of HA in Ruangan Zhuyu formula group decreased significantly (P<0.05). The results of HE, oil red and Masson staining showed that liver fibrosis and liver inflammation were significantly reduced in mice in Ruangan Zhuyu formula medium and high-dose groups.
Ruangan Zhuyu formula can effectively reduce the body mass of mice induced by high-fat diet, and improve the liver function and liver fibrosis of mice.
To explore the curative effect of Yinzhihuang oral liquid on intrahepatic cholestasis of pregnancy (ICP).
A total of 110 ICP patients admitted to our hospital from June 2019 to June 2021 were selected and divided into the control group (ursodeoxycholic acid+adenosyl methionine treatment) and the study group (Yinzhihuang oral liquid was given on the basis of the control group) according to simple sequencing random method, with 55 patients in each group. The clinical efficacy, itching degree, phospholipid transfer protein (PLTP) level and maternal and infant outcomes were compared between the two groups.
Compared with the control group, the total effective rate of the study group was significantly increased (P<0.05). After treatment, the pruritus score, PLTP and fibrinogen of ICP patients in both groups were significantly reduced, the prothrombin time was increased, and the improvement was more obvious in the study group (P<0.05). The total incidence of adverse outcomes in the study group and the control group was 10.91% and 27.27%, respectively, with statistical significance (P<0.05).
Yinzhihuang oral liquid combined with adenosyl-methionine and ursodeoxycholic acid has a better effect in the treatment of ICP patients, which can reduce the degree of pruritus and the expression level of serum PLTP, and improve the coagulation function and newborn outcome.
To investigate the influences of fire needling combined with Huoxue Huayu decoction on the changes in nail fold microcirculation and the level of serum von Willebrand factor (vWF) of patients with psoriasis vulgaris (blood stasis syndrome).
120 patients with psoriasis vulgaris who were treated in our hospital from October 2021 to August 2022 were selected as the research objects. The patients were grouped into fire-needling group, decoction group, and combined group by random number table method, with 40 cases per group. The patients in the fire-needling group were treated with fire-needling on the target skin lesion area, Geshu, Ganshu and Shenshu points, and the patients in the decoction group were treated with self-made Huoxue Huayu decoction orally, and the patients in the combined group were treated with fire needling combined with Huoxue Huayu decoction. The morphological changes of nail fold microcirculation and serum vWF, antithrombin Ⅲ activity (AT-ⅢA), and plasminogen activator inhibitor-1 (PAI-1) levels were compared among the three groups.
After treatment, compared with the fire-needling group and the decoction group, the psoriasis area and severity index (PASI), loop shape, fluid state, and peri-loop state, serum PAI-1 and vWF levels in the combined group were lower (P<0.05), and the serum AT-ⅢA level was higher (P<0.05). At 8 and 12 weeks after treatment, the PASI improvement rate of 75% in the combined group was higher than that of fire-needling group and decoction group (P<0.05).
Fire needling combined with Huoxue Huayu Decoction in the treatment of psoriasis vulgaris can improve the curative effect, reduce skin damage, and improve the morphological changes of nail fold microcirculation and blood hypercoagulability.
To investigate the population characteristics and clinical efficacy of Sheng Xuexiaoban capsules in the treatment of tumor chemotherapy-related thrombocytopenia (CIT) in the real word, and to observe its effectiveness and safety in a wide range of people, the rationality of clinical combination of drugs and the difference in efficacy of different combinations of drugs.
A retrospective study was conducted to select 2 812 CIT patients treated with Sheng Xuexiaoban capsules, and they were divided into four groups according to the combination of drugs, 1 522 patients in treatment group A (Sheng Xuexiaoban capsules alone), 719 patients in treatment group B (combined with recombinant human thrombopoietin injection), 786 patients in treatment group C (combined with interleukin-11), and 9 patients in treatment group D (combined with hexapopethanolamine tablets). The changes of platelet count and CIT grade before and after the treatment were compared.
Compared with before treatment, platelet counts in treatment groups A, B and C all increased after treatment, and the difference was statistically significant (P<0.001). In different treatment stages, the difference of CIT grading among the four groups was statistically significant (P<0.05).
Sheng Xuexiaoban capsules can significantly improve the platelet level of tumor chemotherapy-related thrombocytopenia, especially in combination with recombinant human thrombopoietin injection and interleukin-11, the overall safety is good, worthy of clinical promotion and application.
To evaluate the economy of imaging bulk package contrast agents in CT rooms and explore the clinical application of bulk doses.
Based on contrast agent usage and medical insurance reimbursement of 1 169 patients in the database built by the research team and the hospital management information system, general statistical methods and decision tree model were used to analyze the impact of different specifications of contrast agents on the number of hospital scans. Economic evaluation was conducted by the minimum cost method. Additionally, qualitative interviews were conducted to explore the technical advantages and safety of imaging bulk package contrast agents.
According to the average annual scans of 49 807 patients in the sample hospital, compared with the 100ml (400mg/ml) specification, the 500ml (400mg/ml) specification contrast agent saved an average of 29.60 s of examination time per person. This resulted in an annual increase of 3 890 scan patients, generating an additional revenue of approximately 3.01 million RMB for the hospital. The 500ml (400mg/ml) specification contrast agent, on average, saved medical insurance expenses for each hospital by 12.06—12.79 million RMB annually (a reduction of 52.19%—55.38%). The 500ml (400mg/ml) specification contrast agent also reduced medical waste by an average of 3 832 kg per year, saving waste disposal costs by 13 500 RMB. Qualitative interview results indicated that imaging bulk package contrast agents could save hospital resources to a certain extent and ensure safety at the current technological level.
With the continuous promotion of disease diagnosis-related groups payment models, imaging bulk package contrast agents have lower costs and can reduce resource waste, save nursing staff operation time. This can effectively reduce the economic burden on hospitals, improve the efficiency of medical insurance payment and hospital operation.
To understand the occurrence of adverse events of linezolid in the real world and evaluate its medication safety, and mine adverse event signals of linezolid based on the data from the FDA Adverse Event Reporting System (FAERS) database, to provide reference for clinical drug treatment monitoring.
A total of 23 quarters of linezolid adverse event report data from the first quarter of 2018 to the third quarter of 2023 were screened from the FAERS database. After data cleaning, Medicines and Healthcare Products Regulatory Agency (MHRA) comprehensive method. The correlation of adverse events was measured using ROR values and proportional reporting ratio (PRR).
A total of 26 075 adverse event reports with linezolid as the primary suspected drug were obtained, and 619 adverse event signals were mined. The adverse event signals of linezolid involved systemic diseases and reactions at the administration site, infections and infectious diseases, the blood and lymphatic system diseases, and various examinations. Adverse events with strong signals were found to be minimum inhibitory concentration [ROR 95% confidence interval (CI) lower limit=598.04, PRR=1 904.92], sideroblastic anemia (ROR 95% CI lower limit=515.20, PRR=1 108.32) and mediastinal effusion (ROR 95% CI lower limit=369.74, PRR=1 904.92). At the same time, adverse event signals such as trichoglossia (ROR 95% CI lower limit=97.39, PRR=144.43), choroiditis (ROR 95% CI lower limit=200.02, PRR=306.90) and cavernous transformation of portal vein (ROR 95% CI lower limit=180.90, PRR=507.98) were also identified that were not mentioned in the instructions.
Linezolid needs to be closely monitored for poor treatment efficacy and adverse events/reactions related to the blood system during clinical use. The results of this study also remind medical personnel to pay attention to new adverse event signals with strong signal values during drug treatment monitoring to ensure the safety and effectiveness of clinical medication.
To explore the efficacy and safety of durvalumab combined with cisplatin and docetaxel as neoadjuvant therapy in the treatment of locally advanced non-small cell lung cancer (NSCLC) patients.
This prospective, single-arm clinical study included twenty-five patients with locally advanced NSCLC from January 2020 to March 2021 who received durvalumab combined with cisplatin and docetaxel neoadjuvant therapy for 2 cycles before surgery. Then they received durvalumab monotherapy or combined with cisplatin and docetaxel adjuvant therapy after surgery. After discharge, patients were followed up every 1 to 2 months for the first six months and every 3 to 6 months thereafter. The primary outcome was pathological remission rate. Secondary outcome measures were clinical response rate, disease-free survival (DFS), and overall survival (OS).
The mean age of all enrolled patients was (59.84±7.14) years, including 18 males (72.00%) and 7 females (28.00%). The primary outcome indicated that 56% patients achieved significant pathological response, among which 24% achieved complete pathological response. The secondary outcome showed that 0, 60%, 36% and 4% patients achieved clinical complete response, partial response, disease stability and disease progression, and the overall objective response rate was 60%. The 1-year DFS was 79%, and the 1-year OS was 90%. There was no correlation of Eastern Cooperative Oncology Group performance status and TNM stage with DFS or OS. Besides, The most common adverse events were alopecia (48%), fatigue (40%), nausea and vomiting (36%). Most of the adverse events were at grade 1 to 2, only a few were at grade 3 to 4.
Durvalumab combined with cisplatin and docetaxel exhibits good efficacy profile as neoadjuvant therapy in locally advanced NSCLC patients.
To evaluate the reliability and validity of the application of Shared Decision Making Questionnaire for Phyxicians Chinese version of Shared Decision-making Questionnaire in aesthetic medicine.
The Chinese version of Shared Decision-making Questionnaire was used to survey 50 medical aesthetic practitioners in public and private medical institutions in Shanghai, and a total of 50 valid questionnaires were collected. SPSS22.0 software was used for statistical analysis. Spearman-Brown formula was used to calculate split-half reliability, Cronbach's α coefficient was used to evaluate the internal consistency reliability of the questionnaire. Factor analysis method was used to evaluate the structural validity.
Among the 50 medical beauty practitioners, 66% of which were female, and 92% worked in public medical institutions. The Chinese version of Shared Decision-Making Questionnaire included three scales: Shared decision-making process scale (T1), Shared decision-making barriers scale (T2) and shared decision-making facilitators scale (T3). The split-half reliability coefficients of the three scales were 0.86, 0.91 and 0.84, respectively. Cronbach's α coefficients of the three scales were 0.92, 0.93 and 0.87, respectively. The cumulative variance contribution rates of the three scales were 63.16%, 65.81% and 57.01%, respectively.
The Chinese version of Shared Decision-making Questionnaire developed by the project team has good reliability and validity, which can be applied to evaluate the development of shared decision-making in the field of medical aesthetics, and can also be a tool for doctors to improve compliance of patients with medication and improve the effectiveness of drug treatment.
Nonalcoholic fatty liver disease (NAFLD), as a widespread chronic hepatic disease, is caused by the accumulation of hepatocellular triglyceride, instigating immunological engagement and accompanied by histopathological alterations. NAFLD's a progressive ailment, and the inflammatory response is the driving force in the progression of NAFLD, with various triggers involving metabolic damage often leading to the activation of different immunocytes. The specific drug for NAFLD remains deficient. Stem cell-derived exosomes, representing an innovative therapeutic modality with minimized immunogenicity, are used to suppress the immune reactions in tissues. This article aimed to explore the pathogenesis of NAFLD and the importance of liver in human immunity, discuss the role of different immunocytes in the pathogenesis and progression of NAFLD, deeply understand the pathogenesis of immunocytes involved in NAFLD, summarize the current immunotherapy, and to provide theoretical support for the design of new immunotherapy.
B-cell lymphoma-2 cell death interaction regulator (Bim) is an important component of the B-cell lymphoma (Bcl)-2 family, and is the only protein in the Bcl-2 apoptosis protein family with a BH3 homologous domain. Bim can induce apoptosis by binding to apoptotic members in Bcl-2 through BH3 domain or directly activating pro-apoptotic molecules. The low expression of Bim protein is closely related to the development, prognosis and anti-tumor drug resistance of various tumors. Regulation of Bim protein expression has become a research hotspot. This article reviewed the research progress of Bim protein in antitumor.
Chemotherapeutic drugs are one of the common methods for clinical treatment of tumor diseases. However, chemotherapy-induced peripheral neurotoxicity (CIPN) has become a major factor affecting patients' daily life and work. Mitochondrial damage is one of the main causes of the formation and development of CIPN. When mitochondria are damaged, mitochondrial-derived damage-associated molecular patterns (mtDAMPs) are released into the extracellular environment, which can induce inflammatory responses. Therefore, it is of great significance to explore the mechanism of mtDAMPs in CIPN. However, although there is a large amount of data describing the widespread effects of mtDAMPs on CIPN, the exact mechanism remains unelucidated. Therefore, the mechanism of mtDAMPs induced CIPN and its potential therapeutic agents were reviewed in this paper to provide reference for clinical and non-clinical studies.
There are many eosinophilia-related diseases, with different etiologies and different therapeutic programs. The first-line treatment for non-infectious and non-tumor-related eosinophilia-related diseases is mostly glucocorticoids, which can be combined with immunosuppressive agents according to the severity of the disease. Mepolizumab is a human anti-interleukin-5 monoclonal antibody which has been approved by the FDA for second-line treatment for chronic sinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome. This article reviewed the research progress of mepolizumab in the application of eosinophilia-related diseases except bronchial asthma.
Glaucoma is an irreversible neurodegenerative blinding eye disease that seriously jeopardizes patients' physical and mental health and quality of life. Glaucoma is often accompanied by headache and other symptoms, and the visual findings associated with migraine are similar to those of glaucoma, with vascular risk factors present in pathophysiology. Whether migraine is only a concomitant condition in patients with glaucoma or is a risk factor for glaucoma remains controversial. This article reviewed the epidemiology and pathophysiologic correlations and clinical similarities between glaucoma and migraine, in order to better elucidate the clinical correlation between glaucoma and migraine, to provide a reference for subsequent studies.
Endoscopic submucosal dissection (ESD) is a minimally invasive operation to completely resect the overall mucosal lesions with the assistance of an endoscopy, which is often used for early esophageal cancer and precancerous lesions. However, the mucosal defect caused by ESD is very easy to cause esophageal stenosis, which seriously affects the quality of life of patients. At present, many drugs have been tried for the prevention of ESD postoperative stenosis, and the most successful application is oral and local injection of glucocorticoids. Based on the causes and mechanisms of esophageal stenosis, this article reviewed the preventive drugs especially glucocorticoids for ESD postoperative stenosis.